Quinazoline Crystalline Forms for Brain-Penetrant ErbB2 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-ErbB2 agents, such as monoclonal antibodies, antibody drug conjugates, and tyrosine kinase inhibitors, lack central nervous system penetrability, limiting their efficacy in treating ErbB2 positive breast cancer with brain metastases.
Innovation Solution
Development of new crystalline forms of the quinazoline compound (R)-N-(4-([1,2,4]triazolo[1,5-c]pyrimidin-7-yloxy)-3-methylphenyl)-5-((3,3-difluoro-1-methylpiperidin-4-yl)oxy)-6-methoxyquinazolin-4-amine, including complexes with fumaric acid and free bases, which exhibit improved brain penetration and selectivity against wild type EGFR.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-ErbB2 agents (monoclonal antibodies, ADCs, TKIs) are used, then ErbB2 inhibition is achieved, but central nervous system penetrability is insufficient
Solution Approach 1:
The patent modifies the chemical parameters of the TKI structure by introducing a difluoromethylpiperidin-4-yl group and optimizing the quinazoline core structure. These parameter changes in molecular structure enable the compound to cross the blood-brain barrier while maintaining ErbB2 inhibition activity, thus resolving the contradiction between efficacy and CNS penetrability
Solution Approach 2:
The invention creates a composite molecular structure combining quinazoline core with difluoromethylpiperidine side chain. This composite structure integrates the pharmacophore for ErbB2 binding with structural features that facilitate blood-brain barrier penetration, achieving both reliability and CNS penetrability
2Reliability
If TKIs with high ErbB2 affinity are developed, then tumor inhibition is improved, but selectivity against wild type EGFR may be compromised
Solution Approach 1:
The patent introduces specific local structural features (difluoromethylpiperidin-4-yl group at position 5 and methoxy group at position 6 of quinazoline) that create local binding characteristics. These local quality modifications enable selective interaction with ErbB2 ATP binding site while minimizing interaction with EGFR, thus achieving high tumor inhibition with reduced side effects
Solution Approach 2:
By changing the chemical parameters of the inhibitor structure (introducing fluorine atoms, optimizing ring substitution patterns), the patent achieves differential binding affinity where ErbB2 inhibition is strengthened while EGFR inhibition is selectively reduced, improving the therapeutic index
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
It is disclosed crystalline forms of (R) -N- (4- ( [1, 2, 4] triazolo [1, 5-c]pyrimidin-7-yloxy) -3-methylphenyl) -5- ( (3, 3-difluoro-1-methylpiperidin-4-yl) oxy) -6-methoxyquinazolin-4-amine, methods for the preparation thereof, pharmaceutical compositions comprising one or more of the crystalline forms as an active ingredient, and use of the crystalline forms in the treatment of hyperproliferative diseases.